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Abstract 
Background: Multiple Sclerosis (MS) represents nowadays in Europe the leading 
cause of non-traumatic disabilities in young adults, with more than 700,000 EU cases. 
Although huge strides have been made over the years, MS etiology remains partially 
unknown. Furthermore, the presence of various endogenous and exogenous factors 
can greatly influence the immune response of different individuals, making it difficult 
to study and understand the disease. This becomes more evident in a personalized-
fashion when medical doctors have to choose the best therapy for patient well-being. 
In this optics, the use of stochastic models, capable of taking into consideration all the 
fluctuations due to unknown factors and individual variability, is highly advisable.
Results: We propose a new model to study the immune response in relapsing 
remitting MS (RRMS), the most common form of MS that is characterized by alternate 
episodes of symptom exacerbation (relapses) with periods of disease stability (remis-
sion). In this new model, both the peripheral lymph node/blood vessel and the central 
nervous system are explicitly represented. The model was created and analysed using 
Epimod, our recently developed general framework for modeling complex biological 
systems. Then the effectiveness of our model was shown by modeling the complex 
immunological mechanisms characterizing RRMS during its course and under the DAC 
administration.
Conclusions: Simulation results have proven the ability of the model to reproduce 
in silico the immune T cell balance characterizing RRMS course and the DAC effects. 
Furthermore, they confirmed the importance of a timely intervention on the disease 
course.
Keywords: Multiple sclerosis, Immune system, Computational modeling, Stochastic 
modeling, Petri net
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Background
In the last years computational models have acquired a pivotal role to assure the safety 
and effectiveness of medical treatments independently from the biological, immunologi-
cal, epigenetic and environmental features characterizing each patient. Recently, many 
regulatory agencies are opening to put beside clinical trials the large scale simulations 
on virtual patients. The in silico models are decisive when the individual variability can 
not be captured due to the lack of information about the disease, or simply because of 
unpredictable environmental events; for these reasons some of the individuals variability 
can only be captured by exploiting stochastic approaches.
Computational models could give a considerable advance in the study of diseases char-
acterized by a partially understood etiology, for example Multiple Sclerosis (MS). MS is 
a chronic and potentially highly disabling disease with considerable social impacts and 
economic consequences. Since more than 700,000 European people suffer from MS, it is 
the leading cause of non-traumatic disabilities in young adults [1].
The scientific community agrees that MS involves a process mediated by immune sys-
tem in which an abnormal response of the body’s immune defense is directed against 
the Central Nervous System (CNS) suffer which is made up of brain, spinal cord and 
optic nerves. Within the CNS the immune system activates an inflammation process 
that damages the myelin (i.e. the fatty substance that surrounds and insulates the nerve 
fibers), the nerve fibers themselves and the cells specialized in myelin production (i.e. 
Oligodentrocytes (ODC)).
The myelin degradation process is mediated by self-reactive T cells which are activated 
in the peripheral lymph nodes and secrete pro-inflammatory cytokines (mainly Inter-
feron gamma (IFNγ ) and Interleukin-17 (IL-17)). Among them IL-17 producing T cells 
sustain the pathogenesis of MS by promoting Blood-Brain Barrier (BBB) disruption and 
inducing autoimmune inflammation in the CNS [2, 3]. Furthermore, IL-17 producing 
T cells are increased in the peripheral blood [4, 5], in the cerebrospinal fluid and in the 
CNS perivascular space of MS patients [5, 6]. These self-reactive T cells can be found 
also in healthy subjects but are strictly controlled by various mechanisms including sup-
pression by T Regulatory (Treg) cells. In MS patients Treg cells are impaired in num-
ber and function [7] and allow self-reactive T cells to expand in the periphery, cross the 
BBB and reach the CNS, where they undergo into a secondary re-activation and induce 
demyelination and axonal damage [8, 9]. The triggers that convert the innocuous self-
reactive T lymphocytes into pathogenic are still not understood, but a combination of 
genetic and environmental factors (e.g. Epstein-Barr Virus, vitamine D and smoking) 
[10] seems to be implicated.
The alteration or completely interruption of nervous messages within the CNS pro-
duces a variety of neurological symptoms that will vary among MS patients in type and 
severity. MS patients typically experience one of four disease patterns (types of MS) with 
a predominance of the Relapsing Remitting Multiple Sclerosis (RRMS) course observed 
in approximately 85% of patients at diagnosis [11]. RRMS patients alternate episodes of 
symptom exacerbation (relapses) with periods of disease stability with complete or par-
tial recovery (remissions) [1].
Until now a dozen treatments have been proposed to reduce the frequency of MS 
relapses, slow the accumulation of disabilities and contrast the RRMS progression. Such 
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disease modifying therapies include oral agents and monoclonal antibodies (mAbs), 
which have been designed for a selectivity of drug action. Among mAbs Daclizumab 
(DAC) was selected for its ability to bind the CD25 sub-unit of the high-affinity Inter-
leukin-2 receptor (IL-2R). IL-2R is a receptor-structure able to bind a key component of 
the immune system, Interleukin-2 (IL-2), a cytokine that allows T cell proliferation. DAC 
introduced a new mechanism of action preventing the binding of IL-2 to its receptor 
with a consequent effect on immune cells which involves the blockade of T effector cells 
activation, the reduction of Treg cells and the increase of a particular Natural Killer (NK) 
cells subset with regulatory ability [11]. DAC efficacy was demonstrated in reducing 
(i) the clinical relapse rate of RRMS, (ii) the disability progression, and (iii) in improv-
ing health-related quality of life [11]. DAC appears to be generally well tolerated by MS 
patients with some adverse events as infections, encephalitis, and liver damages. How-
ever, the safety and efficacy results obtained after eight years of DAC treatment from the 
clinical trials were finally published [12]. The study and the simulation of RRMS course 
during DAC administration involves a series of hypotheses about the disease mecha-
nisms that cannot be always described through a deterministic process. Environmental 
events, the complex balance mechanism between the T Effector (Teff) and Treg cells, 
or the random spreads of self-reactive T cells cannot be well predicted, and fall within 
that part of uncertainty that cannot be quantified and that can potentially distinguish 
the disease course of different individuals, even with the same genetic background. In 
this perspective some stochastic models of RRMS have been presented in the literature. 
Vélez de Mendizábal et al. [13] presented a Stochastic Differential Equation (SDE) model 
to reproduce the typical oscillating behavior of RRMS. In [14] the authors presented a 
(stochastic) agent based model with a more complete description of the entities involved 
into the disease, including some thoughts about the role of vitamin D [15], and the BBB 
[16]. However, these models can not be easily re-used because their analysis workflows 
are often so specific that they can not be directly applied to analyze other contexts differ-
ent from those for which they were originally developed. To deal with this aspect, in this 
work we developed a new RRMS model and its associated analysis workflow using Epi-
mod [17], a general modeling framework that we recently developed to provide a friendly 
environment for the modeling and the analysis of complex biological networks. Briefly, 
the Epimod utilization allows us: (1) to use a graphical formalism for the model creation; 
(2) to implement the analysis workflow exploiting a user-friendly interface based on R 
language; (3) to achieve the computational reproducibility of the analysis results; (4) to 
have the possibility to easily create new user-defined analysis workflows.
In detail the new RRMS model extends those proposed in our previous works [18, 
19], including new biological components of the immune system relevant to MS dis-
ease: (1) the BBB, that mainly has the function of protecting brain tissue from harmful 
elements present in the blood and that in MS is damaged and crossed by T cells [20]; 
(2) pro-inflammatory (e.g. IL-17, IFNγ ) and anti-inflammatory (e.g. Interleukin-10 (IL-
10)) cytokines, cell signaling molecules that modulate the immune response through 
the activation of several pathways [20]. Moreover, the model is calibrated by exploring 
experimental data on 16 subjects, eight MS patients and eight healthy donors, in which 
the individual variability in terms of number of cells and cytokines production, in the 
blood and in the cerebrospinal fluid, had been quantified [5]. Then, the model behaviour 
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without and with DAC administration was studied using Stochastic Simulation Algo-
rithm (SSA) [21] method implemented in the R package Epimod [17] in order to take 
into account the stochasticity and the variability of the MS desease.
Methods
In this section we introduce the high-level Petri Net (PN) extension, called Extended 
Stochastic Symmetric Net (ESSN) [18], which is used to graphically model our case 
study. Then, we report how the behaviour of such a system can be efficiently derived by 
exploiting SSA algorithm. Finally, we briefly introduced the Epimod framework exploited 
in this work to achieve an easy reusable model by other researchers and a reproducible 
analysis.
Extended stochastic symmetric net
PNs [22] and their extensions are widely recognized to be a powerful tool for modeling 
and studying biological systems thanks to their ability of representing systems in a graph-
ical manner and allowing the computation of qualitative and quantitative information 
about the behavior of these systems. In details PNs are bipartite directed graphs with 
two types of nodes, the former is called place and it is graphically represented as circle, 
the latter is called transition and it is graphically represented as box. Usually, places cor-
respond to the state variables of the system and they can contain tokens encoding the 
corresponding variable state. Otherwise, transitions represent events that might occur 
in the system. These two different nodes are connected by arcs, which express the rela-
tion between states and event occurrences. A specific cardinality (multiplicity) is asso-
ciated with each arc describing the number of tokens removed from (or added to) the 
corresponding place upon the firing of the transition the arc is connected to. Graphically 
it is written beside the arc, but the default value of one is omitted. Then, the number of 
tokens in each place defines the state of a PN, called marking.
We define a transition enabled, if and only if each input place contains a number of 
colored tokens greater or equal than a given threshold defined by the cardinality of the 
corresponding input arcs. Thus, the firing of an enabled transition removes a fixed num-
ber of tokens from its input places and adds a fixed number of tokens into its output 
places, according to the cardinality of its input/output arcs.
Among the PNs generalisations proposed in literature, ESSNs [18, 23] extend the PN 
formalism providing a more compact, parametric, and readable representation of the 
system. ESSN allow also an easy definition of complex rate functions splitting the set of 
transitions T in two sub-sets Tma and Tg . The subset Tma represents the standard transi-
tions which fire with a rate following a Mass Action (MA) law. While Tg is represented 
by the general transitions, whose random firing delays have rates that are defined as gen-
eral real functions that might depend only from the time and the corresponding input 
places. The standard transitions are graphically represented by white bars, while the gen-
eral ones by black bars.
An example of a simple ESSN is given in Fig. 1 where the activation inside the CNS of 
the Teff cells due to the myelin sheaths is modeled. Furthermore, the activation veloc-
ity depends on the inflammatory cytokines IFNγ which are produced by the Teff them-
selves. This is a portion of the more complex ESSN model represented in Fig. 3, and it 
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is characterized by three places, Teff_in, IFNg_in and ODC, representing the Effector T 
cells, IFNγ cells, and the Oligodentrocytes cells, respectively. This model includes: (1) 
two standard transitions Teff_to_NLT and Teff_prod_IFNg representing the Teff cells 
death and the IFNγ production; and (2) two general transitions TeffActivation_in, and 
TeffKillsODC modeling the activation of the Teff cells and the damage of the mylen 
sheets.
In order to associate colors with the tokens, we have to define a color domain for each 
place p, denoted cd(p) . Color domains are defined by the Cartesian product of elemen-
tary types called color classes, C = {C1, . . . ,Cn} , which are finite and disjoint sets, and 
might be further partitioned into (static) subclasses. They can be ordered (in this case 
a successor function is defined on the class, denoted by ++, inducing a circular order 
among the elements in the class), and can be partitioned into (static) subclasses. Simi-
larly, a color domain is associated with transitions and is defined as a set of typed vari-
ables where the variables are those appearing in the functions labeling the transition arcs 
and their types are the color classes. Then, we can define an instance, denoted as 〈t, c〉 , of 
a given transition t as an assignment (or binding) c of the transition variables to a specific 
color of a proper type. Moreover, we define guard a logical expression defined on the 
color domain of the transition which can be used to define restrictions on the allowed 
instances of a transition. For instance, in the example in the Fig. 1 the ODC color domain 
is defined by one color class, the myelination levels of ODC cells, named Mye. This is 
divided into 5 static subclasses (i.e. Lmin, L1, L2, L3 and Lmax ) so that myelination level 
ranges from an irreversible damage ( Lmin , no myelination) to no damages ( Lmax , full 
myelination). So, the color domain of TeffKillsODC transition, representing the damage 
of an ODC cell, is Mye and the variable characterizing its input arc is l ∈ Mye.
Each ESSN arc is labeled with an expression defined by the function I[p, t] , if the arc 
connects a place p to a transition t, or O[p, t] for the opposite direction. The evalua-
tion of I[p, t] (resp. O[p, t] ), given a legal binding of t, provides the multi set of colored 
tokens that will be withdrawn from (input arc) or will be added to (output arc) the 
place connected to that arc by the firing of such transition instance. Moreover, we 
denote with •t and t• the set of input and output places, respectively, of the transition 
Fig. 1 Subnet of ESSN model presented in Fig. 3, representing the Teff activation in CNS, the production of 
the INFg and the damage the ODCs. Mye is circolar color class, representing the myelination levels of ODC 
cells. This is divided into 5 static subclasses: Lmin , L1, L2, L3 and Lmax . l is a variable belonging to the color 
class Mye. Moreover the successor operator applied on l (i.e. l ++ ) is exploited to increase the damage level 
of an ODC cell. Finally the guard [l /∈ Lmax ] associated with transition TeffKills ODC ensures that only ODC cells 
with damage level different by Lmax can be attacked by a Teff cell
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t. We use the notation E(t, m) to denote the set of all instances of t enabled in mark-
ing m. Where, in the case of ESSN formalism, a transition instance 〈t, c〉 is enabled and 
can fire in an marking m, if: (1) its guard evaluated on c is true; (2) for each place p we 
have that I[p, t](c) ≤ m(p) , where ≤ is the comparison operator among multi sets. The 
firing of the enabled transition instance 〈t, c〉 in m produces a new marking m′ such 
that, for each place p, we have m′(p) = m(p)+ O[p, t](c)− I[p, t](c).
In ESSNs each transition is associated with a specific rate, representing the param-
eter of the exponential distribution that simulates its firing time. So, let define 
m̂(ν) = m(ν)|•t as the subset of the marking m(ν) concerning only the input places to 
the transition t. Then, the parameter associated with an enabled transition instance 
〈t, c〉 is given by the function
where � = {f�t,c�}t∈T∧c∈cd(t) is set grouping all the real functions characterizing the tran-
sition speeds ∀t ∈ T  , with f�t,c� = ϕ(·, t, c) when t ∈ Tma . Where ϕ(m(ν), t, c) is the MA 
law, i.e.
with ω(t, c) the rate of the enabled transition instance 〈t, c〉 . Observe that ϕ(m̂(ν), t, c) 
and f�t,c�(m̂(ν), ν) can depend only on the time ν and the marking of the input places 
of transition t at time ν . Stochastic firing delays, sampled from a negative exponential 
distribution, allow one to automatically derive the underlying Continuous Time Markov 
Chain (CTMC) that can be studied to quantitatively evaluate the system behaviour [22]. 
In details, the CTMC state space, S , corresponds to the reachability set of the corre-
sponding ESSN, i.e. all possible markings that can be reached from the initial marking. 
Thus, the Master equations for the CTMC are defined as follows:
where π(mi, ν) represents the probability to be in marking mi at time ν , and qmk ,mi the 
velocity to reach the marking mi from mk , defined as
where E(t,mk)|mi is the set of all instances of t enabled in marking mk whose firing bring 
to the marking mk , and L[p, t](c′)[c] = O[p, t](c′)[c] − I[p, t](c′)[c].
In complex systems these Eq. 2 are often computationally intractable, then several 
techniques, such as the Monte Carlo simulation, can be exploited to study the system 
taking into account stochasticity.
(1)
F(m̂(ν), t, c, ν) :=
{
ϕ(m̂(ν), t, c), t ∈ Tma,
f�t,c�(m̂(ν), ν), t ∈ Tg ,
f�t,c� ∈ �(t, c)
ϕ(m(ν), t, c) = ω(t, c)
∏














T �t, c′� ∈ E(t,mk)|mi
F(mk , t, c
′, ν)(L[p, t](c′)[c]).
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Stochastic simulation
Deterministic approximation, in which the system behaviour is approximated by a deter-
ministic model described through an Ordinary Differential Equation (ODE)s system, is 
one of the most used approach for studying a dynamical system. However, this approach 
is not able to provide a good approximation of the real system behaviour in those systems 
in which the randomness plays an important role. To deal with these systems stochastic 
approaches can be instead exploited.
In 1976 Daniel Gillespie proposed an innovative algorithm, called Stochastic Simulation 
Algorithm (SSA) [21], to simulate chemical or biochemical systems of reactions. The SSA 
is an exact stochastic method to simulate chemical systems which provides a set of sample 
trajectories distributed according to the solution of the Master equations, Eqs. 2. Since this 
method explicitly simulates all the events that might occur in the system, it becomes often 
slow when the number of system molecules increased. For this reason several algorithms 
[24–26] were proposed for obtaining similar approximations as the SSA ones, but with sig-
nificantly lower computational costs. One of the most common of these approximate simu-
lation algorithms is the τ-leaping algorithm [25]. Indeed by using a Poisson approximation 
the τ-leaping algorithm can leap over many fast reactions and approximate the stochastic 
behavior of the system very well. Then it provides a natural connection between the SSA 
in the discrete stochastic regime and the explicit Euler method applied in the continuous 
deterministic approximation.
Framework
The creation and analysis of the proposed MS model was carried out using the Epimod 
framework [17]. Epimod is an R package providing a modeling framework for the analysis 
of epidemiological and biological systems, which provides the generation of the determin-
istic and stochastic process starting from the ESSN graphical formalism, and allows user 
to carry out the sensitivity, the calibration and the model analysis. In details, by exploiting 
GreatSPN editor [27], a Java Graphic User Interface (GUI), it is possible to draw and build 
the ESSN model, and using the generation model function implemented in Epimod is pos-
sible to easily derive the underlying stochastic and deterministic processes. Successively, the 
sensitivity analysis reduces the search space associated with each unknown parameter, the 
calibration analysis adjusts the parameters to obtain the expected behaviour with respect to 
the available data, and finally the model analysis solves the calibrated model to answer spe-
cific questions and to derive new insights. Finally all the implemented analysis techniques 
were containerized into Docker image to improve the framework portability and to ensure 
the reproducibility of the derived results. The architecture of this framework is depicted in 
Fig. 2.
Finally, let us underline that the GreatSPN GUI can be downloaded at https ://githu 
b.com/great spn, the R package Epimod at https ://githu b.com/qBioT urin/epimo d, and all 
the files exploited through the analysis are freely available at https ://githu b.com/qBioT urin/
Multi ple-Scler osis.
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Results
In this section we first describe the computational model developed to study RRMS 
and then the data exploited to calibrate the model parameters; in particular two param-
eter configurations are identified for healthy and MS subjects. Finally, we discuss two 
therapy scenarios in which we investigated the effect of the DAC administration on MS 
patients. All the analyses are performed on a server with 6 Intel Xeon E5-2650 proces-
sors (2.00Ghz, 20MB Cache, 8 Cores) by exploiting Epimod.
Model description
The cellular interactions characterizing the immunopathology of RRMS are described by 
the model showed in Fig. 3. The model consists of 26 places and 55 transitions, of these 
40 are standard and 15 general. Observe that to make immediately clear the biological 
role of each place in the net, we decided to represent them using four different icons 
whose meaning is reported in the legend of Fig. 3. In details, the model is divided in two 
compartments: the peripheral lymph node/blood vessel and the CNS. The two compart-
ments interact with each other through the place BBB, as illustrated in Fig. 3. All transi-
tions describing interactions occurring in peripheral lymph node/blood vessel have the 
suffix “_out” while all transitions taking place in CNS have the suffix “_in”. The Antigen 
place, simulates the first pathogen infection and then the infection reactivation in the 
system through the AntigenInjection transition.
In the peripheral lymph node compartment of the net the places regarding the Teff 
cells, including Effector Memory T cells, are represented. After pathogen infection 
Teff cells can give rise to Teff or Effector memory cell through TeffDup_Sym_out and 
TeffDup_Asym_out transitions. Effector memory cells remain in this compartment 
and are able to respond faster to the infection reactivation. The annihilation of the 
pathogen by the Teff action is modeled by the transition TeffKillsA, while symmet-
rical and asymmetrical duplication of Teff cells is encoded by transitions TeffDup_
Sym_out and TeffDup_Asym_out. Teff production of the inflammatory cytokines 
IL-17 and IFNγ is represented by the transitions Teff_prod_IL17 and Teff_prod_IFNg, 
Fig. 2 Framework
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respectively. Inflammatory cytokines are degradated by IFNgConsumption_out and 
IL17Consuption_out transitions. Afterwards, the arrival of new resting Treg cells 
from thymus, the control mechanism of the Treg over the Teff and their activation, 
proliferation and death are encoded by the transitions FromTimoReg, TregKillsTeff_
out, TregActivation_out, TregDup_out and TregDeath, respectively. Treg production 
and degradation of the anti-inflammatory cytokines IL-10 are represented by the 
transitions Treg_prod_IL10_out and IL10Consuption_out.
Through the transition NKarrive the arrival of a NK cells able to kill self-reactive 
Teff is simulated. The killing is simulated by the transition NKKillsTeff_out and the 








































































Fig. 3 RRMS Model represented by exploiting the ESSN graphical formalism. Each places has on top a sketch 
of its biological role as described by the legend
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and NK_prod_IL10, respectively. The death and proliferation of the NK cells are mod-
eled by transition NKDegradation and NKdup.
The drug administration of daclizumab (DAC) is modeled by transition DACinjection, 
and its degradation by DACDegradation. DAC is able to inhibit the expansion of Treg 
and Teff through the transitions DACkillTeff and DACkillTreg.
During the relapsing phases of the disease the BBB increases its permeability leading 
to the passage of Teff and Treg from peripheral blood to CNS . This biological process 
is encoded by the place BBB and transitions Teff_pass_BBB, Treg_pass_BBB, IL10_BBB 
and IL17_BBB.
In the CNS the Resting_Teff_in are activated through the transition TeffActivation_in. 
The ODC damage due to Activated Teff cells is modeled by TeffKillsODC whose its fire 
decreases the myelination levels of ODC s by acting on the colors of the tokens in place 
ODC1. When the myelin level reaches the lowest value, an irreversible damage occurs 
since the remyelinization of the neurons modeled by the transition Remyelinization is no 
longer possible.
Finally, transition TeffDup_Sym_in simulates the Teff cells proliferation. Teff produc-
tion of the inflammatory cytokines IL-17 and IFNγ is represented by the transitions 
Teff_prod_IL17_in and Teff_prod_IFNg_in, respectively. The inflammatory cytokines are 
degraded by IFNgConsumption_out and IL17Consuption_in transitions.
Tregs in CNS (Resting_Treg_in and Treg_in) product and degrade IL-10 thought Tref_
prod_IL10_in and IL10Consuption_in. Their control mechanism on Teff their activation, 
proliferation and death are encoded by following transitions: TregkillsTeff_in, TregDup_
in and Treg_to_NLT.
Parameters, constants and functions are reported in Additional file 1, S1.1.
Data
For the calibration of the model we used biological data from eight relapsing MS patients 
and eight healthy donors (Healthy Donors (HD)s). A blood sample and a cerebrospinal 
fluid (CSF) sample of MS subjects were collected at the onset of the disease. Since CSF 
withdrawal is an invasive practice, for HDs only a blood sample was obtained. The flow 
cytometer cell counts have been used to set the initial marking of the net. In details, the 
cells were isolated from blood and in-vitro activated as specified in the methods sec-
tion of [5]. After 18 hours cells were “tagged” with a mixture of fluorescent antibodies 
directed towards proteins that identify the culture of interest. Regarding T cells, the 
combinations of multiple antibodies can be used to identify a specific cellular subtype of 
interest. In our case, the total of CD4+ T cells / ml of blood or CD4+ T cells / ml of CSF 
was counted, and, among them, the percentage of cells producing IL-17, IFNγ or IL-10 
in blood and CSF was identified, see Table 1.
The individual cell counts of MS patients and healthy subjects were used to fit the 
model parameters.
1 Observe that the tokens in ODC are colored according to color class Mye  that is divided into five static subclasses 
ranging from Lmin (no myelination) to Lmax (full myelination) of the color class
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Model calibration
The model calibration was performed on our model to make its behaviours in agree-
ment with the experimental values described above. In details, during the calibration 
analysis the same initial marking was assumed for both HDs and MS patients, as showed 
in Table 2, where only the places with initial marking different from zero were reported. 
Observe that these values correspond to the average values computed considering only 
the HDs reported in Table 1. Moreover, we considered all the 500 ODC with level Lmax 
of neuronal myelinization at the initial time.
Then, from the model shown in Fig. 3 a system of 26 ODEs composed by 20 unknown 
parameters was derived. These parameters (reported in Table S1 in the Additional file 1) 




















MS1 169.22 30.83 3.52 13.24 3.31 0.06
MS2 21.56 5.33 1.02 5.59 1.71 0.06
MS3 71.10 15.45 2.46 16.10 0.60 0.10
MS4 15.44 21.34 1.54 3.36 0.88 0.04
MS5 148.65 28.66 2.27 17.80 2.87 0.10
MS6 60.31 15.80 4.38 12.27 1.18 0.14
MS7 377.13 53.86 5.13 29.64 2.29 0.11
MS8 156.74 21.87 8.26 10.15 1.64 0.13
mean MS 117 25 3 12.77 1.85 0.09
HD1 42.37 21.19 26.98 0.30 0.30 0.40
HD2 2.40 13.20 16.80 0.80 0.20 1.00
HD3 8.70 7.83 8.18 0.20 0.80 1.00
HD4 69.30 3.15 11.76 1.00 1.00 1.00
HD5 16.15 2.38 8.27 0.10 0.80 0.10
HD6 18.45 1.64 6.48 2.00 1.00 2.00
HD7 63.00 7.88 10.94 0.10 0.10 0.80
HD8 97.27 13.70 12.06 0.20 1.90 1.90
mean HD 42 8 13 0.59 0.76 1.03
Table 2 Initial marking of the model
Place Number of cells/mm3 Reference
Resting_Teff_out 1689 [18]
Resting_Treg_out 63 [18]
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were characterized by a high uncertainty due to their difficulty of being empirically 
measured. To identify the parameter values, the ODE system was simulated over 30 days 
interval assuming a injection of 100 antigen copies at the second day. This analysis lead 
to identify the best fit characterized by the values described in Sec. Data. In particular, 
the parameter values for HD and MS patient were identified by minimizing the differ-
ence between the numbers of IFNγ-producing, IL-17-producing IL-10-producing cells 
in blood and in CSF obtained from the solution of the ODE system and those experi-
mentally measured in average for HDs and MS patients (reported in Table 1) after 18 
hours from the antigen injection.
It is worth noting that the two sets of parameter values, respectively for HD and MS 
patients, obtained by the calibration step, differ only in the values of the parameters 
pTreg_Activation and pTeff _Activation associated with the transitions TregActivation_in(_out) 
and TeffActivation_in(_out).
The model behaviours derived by these two parameter configurations are reported in 
Figure S2 of the Additional file 1. From these plots it is immediately clear that the model 
outcomes are in agreement with real data and the current knowledge of MS disease, for 
example the MS patients are characterized by a higher number of irreversibly damaged 
ODC cells and a more impermeable BBB than HDs.
Stochastic simulations After the model calibration, the two parameter configurations 
were exploited to investigate the stochastic behaviour of the system using the SSA algo-
rithm. In Fig. 4, 1000 trajectories for each scenario are plotted in grey, while the colored 
bold line represents the mean trajectory. The distribution of experimental data (Table 1) 
is represented through violin plots. It is possible to observe that the mean trajectory and 
the set of 1000 stochastic trajectories are consistent with the experimental measures 
in both HDs and MS patients. In particular, observing the 1st row in Fig.  4, it is pos-
sible to appreciate the differences in the number of circulating Treg cells between HD 
and MS patient. Accordingly, while the antigen is counteracted by the Teff cells, Treg 
cells try to balance the aggressiveness of the immune system and to maintain the cellu-
lar homeostasis by acting as a brake on the inflammatory response producing IL-10and 
killing Teff cells. In the 2nd row in Fig.4 the IL-10 dynamics are reported: the MS condi-
tion produces less IL-10 with respect to the healthy counterpart. IL-10 cytokines imbal-
ance towards an inflammatory state is reflected in an increased permeability of the BBB. 
IL-10 contributes to promote BBB integrity, while IL-17 contributes to the damage of 
BBB, making it permeable to the passage of cells of the immune system and other mol-
ecules. Indeed, after less than one week we can observe that in the MS patient BBB has 
the highest permeability ( 3rd row in Fig.4) leading to a T cell trafficking in the CNS. This 
effect is observed in the form of an increased reactivation of Teff cells in the CNS of the 
MS patient compared to the healthy subject ( 4th row in Fig.4), as well as in the increase 
in the circulation of pro-inflammatory cytokines produced by the Teff cells circulating 
in the CNS: IL-17 ( 5th row Fig.4) and IFNγ ( 6th row Fig.4). The final result of this pro-
inflammatory environment in the CNS is an increased damage to the ODCs, which sim-
ulates a neuronal damage to the myelin in the CNS actually observed during the clinical 
relapse ( 7th row and second column Fig.4). Conversely, ODC damage is not observable 
in HDs ( 7th row and first column Fig.4). The dynamics of the other cells are reported in 
Figure S3 of the Additional file 1.
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Daclizumab therapy
To investigate the effect of the DAC therapy in our model calibrated for RRMS 
patients, we simulated a real scenario with multiple antigen occurrences at differ-
ent time in two-years time interval. In details we assumed a total of eight injections 
introducing into the system 100 antigen copies per injection. Most of the MS-related 
viruses, infect a particular type of immune cells (i.e. the Epstein-Barr Virus (EBV) 
infects B cells) and once the initial lytic infection is brought under control, the virus 






















































Fig. 4 1000 stochastic simulations considering the healthy (first column) and the MS (second column) 
parameters configuration. The colored bold lines represent the mean traces of the simulations, blue for the 
healthy and red for the MS scenario. The violin plots are the representation of the real data
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rest of his/her life and is subjected to periodical reactivation [30]. For this reason, we 
defined a sequence of injections at varying intervals: the first three injections were set 
at constant time interval, i.e., the 2nd, 67th and 127th day, then four consecutive injec-
tions were simulated at 295th, 300th, 303th and 307th days, and finally the last injec-
tion at 600th days. Two important aspects of the therapy modulation were considered 
in our simulations: the drug dose and the drug potency. In details, five scenarios char-
acterized with an increasing drug dose (i.e., 1000, 2000, 5000, 10000 and 15000) were 
analysed. Then for each scenario two drug potencies (i.e. weak potency and strong 
potency characterized by DACkillTreg and DACkillTeff set to 0.01 and 0.03, respec-
tively) are showed for a total of ten different scenarios. These scenarios are proposed 
in two course of actions: early regime therapy in which the DAC administration starts 
at the first month, and late regime therapy in which the DAC administration starts at 
the sixth month.
In Fig. 5 and Fig. 6 the behaviour of the places Antigen, Teff_out, IFNg_out, IL17_out, 
Treg_out, IL10_out, NK_out, BBB, and ODC irreversibly damaged in the early and late 
regime are reported. In each figure, the columns represent nine scenarios among the 
twelve described above. Specifically, we decide to omit for clarity the healthy scenario 
and the ones considering drug dose equals to 2000. The colored bold lines represent the 
median of 1000 simulations, while the colored areas are the range of the simulations 
between the first and third quartile. In the Fig.s S4-S5 in the Additional file 1, the com-
plete list of cell types for all the scenarios in both the regime considered are reported.
Fig. 5 Stochastic simulations considering the early therapy. Different colors are associated to quantity of 
DAC injected for each scenario, from 1000 to 15000 cells. The first two column represent the healthy and MS 
scenarios. Two drug potencies (called DP) are showed, i.e., 0.01 e 0.03
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In both Figs. 5 and 6,the reduction of circulating Teffs and Tregs is visible in all treat-
ment conditions (the 2nd and 5th rows), with a remarkable effect at increasing doses. 
The same effect is visible in the amount of cytokines produced by T cells (the 3rd , 4th 
and 6th row). Although the DAC is unable to cross the BBB and spread in the CNS, these 
effects are observable either in the blood and in the CNS (Fig.s S4-S5 in the Additional 
file 1). This is due to a reduced number of T cells that are not able to effectively reach the 
CNS and to cause damage. Indeed, the immunosuppressive action of DAC is mediated 
by the binding to CD25 molecules of IL-2R, present on activated Teff cell and on Treg 
cells, and results in the inhibition of their proliferation and in the induction of T cell 
death.
Figure 7 shows the number of irreversibly damaged ODC (the blue contour boxplot) 
and the overall antigen concentration (the red contour boxplot) for each scenario. In 
details, it is showed the difference in the total amount of irreversibly damaged ODCs at 
the end of the two years, a behavior reflecting the protective effect of DAC therapy on 
the CNS.
It is observed that for the same dose and potency of DAC, the number of irreversibly 
damaged ODCs is lower in “early therapy” than in the “late therapy” condition (Fig. 7). 
Indeed, clinical practice suggests that, in MS, the early intervention reduce neuronal 
damage and long-term disability [31].
Moreover, an interesting effect of DAC therapy visible by our simulations is that 
increasing dose and potency of DAC can suppress the immune system by depleting T 
Fig. 6 Stochastic simulations considering the late therapy. Different colors are associated to quantity of 
DAC injected for each scenario, from 1000 to 15000 cells. The first two column represent the healthy and MS 
scenarios. Two drug potencies (called DP) are showed, i.e., 0.01 e 0.03
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cells and cytokine diffusion. An overdose of the drug reproduces an immuno-compro-
mised immune system, where T cells are depleted and the antigen persists in the cir-
culation. This is visible in Fig.  7 where the red contours boxplots report the antigen 
concentration. It is straightforward to see that increasing drug dose is associated with 
a minor ODC damage at the expense of the antigen annihilation. Moreover, a stronger 
drug potency is not positive either from the ODC damage and the antigen annihilation 
point of view. The ideal dose of DAC is a trade-off between antigen annihilation and a 
reduction in damaged ODC. Drug efficacy must occur with a consideration of the pro-
tection from external antigens to minimize the risk of secondary infections - sometimes 
with serious adverse effects - that often accompany immuno-suppressive therapies in 
MS [32].
Discussion
In immunology the use of computational modeling is quite recent, but it is becoming 
increasingly important. In particular, the computational models can help the researchers 
to discern between potential right and wrong biological hypotheses, whose confirmation 
cannot be acquired through in vivo or in vitro experiments, to find novel treatments, 
to validate or deduce the mechanisms of actions of existing ones, and to optimize tim-
ing and dosage of treatments. The use of such in silico approaches is gaining attention 
also by regulatory agencies that are starting to foster their application also in the field of 
personalized-medicine.
Fig. 7 Box-plots representing the 1000 trajectories for each type of (i) therapy (i.e., early and late therapy, and 
the healthy an MS cases without therapy), (ii) quantity of DAC injected, and (iii) the drug potency. The ODC 
irreversibly damaged at the end of the two years are plotted with the blue boxplot contour (referring to the 
left blue y-axis), differently the areas under the antigen curve over the whole two years interval are showed 
with the red boxplot contour (referring to the right red y-axis)
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In this context, the construction of mathematical models and their solutions remain 
a challenging tasks mainly due to the lack of general framework easily accessible even 
by researchers without advanced modelling and mathematical skills. To deal with this 
aspect, we proposed Epimod [17] a general modeling framework specifically developed 
to provide a friendly environment for the modeling and the analysis of complex biologi-
cal systems.
In this work, we went a further step forward showing how Epimod can be efficiently 
exploited to study RRMS disease in silico. In details, we extended our previous models 
[18, 19], including different actors of the pathogenetic mechanisms of MS, as the blood 
brain barrier and some cytokines produced by self-reactive Teff cells that in MS over-
come the BBB and reach the CNS where they damage ODCs [9, 33].
Several evidences suggest the association of viral (and, to a lesser extent, also bacte-
rial) infections with disease onset and relapses leading to hypothesize that RRMS course 
could be related to a reactivation of a latent infection [33, 34]. EBV, Human Herpes 
Virus 6 (HHV-6), Varicella Zoster Virus (VZV), and Human Endogenous RetroViruses 
(HERVs) infections can cause the activation of auto-reactive Teff cells against the CNS 
[30, 33, 34] through a mechanism called “molecular mimicry”. This is the most fre-
quently discussed mechanism for how viruses or bacteria could induce autoimmunity 
in MS, that occurs when peptides from pathogens (antigens) share sequence or struc-
tural homology with host peptides (self-antigens), in the case of MS with CNS antigens 
(e.g. Myelin Basic Protein, Myelin oligodendrocyte glycoprotein) [35]. When Teff cells 
encounter such a foreign peptide, they produce IFNγ and IL-17, potent inflammatory 
mediators able to increase the inflammatory micro-environment. In a healthy host 
Teff response is tightly regulated by Treg cells to mediate effective host defense against 
pathogens without causing excessive tissue damage. Furthermore, Treg cells play an 
important role in maintaining peripheral tolerance to self-antigens. In MS patients, low 
number and impaired function of Treg cells [7] could explain the massive production of 
IFNγ and IL-17, during the exacerbation phases of MS. In this context, NK cells also give 
a contribution acting as first-line defense against viruses and bacteria and regulating the 
auto-reactive Teff cells activity, producing the pro-inflammatory cytokine IFNγ and the 
anti-inflammatory cytokine IL-10 [28, 29].
Interestingly, our healthy and MS model differ just in the two parameters associated 
to the activation of Teff and and Treg cells. By increasing the Teff and reducing the Treg 
ones, we were able 1) to fit the real data and 2) to represent the Teff-Treg cell balance 
characterizing the healthy subject and its unbalance in the MS patient.
Current therapeutic strategies for MS are now focusing on the (i) reduction of the risk 
of relapses avoiding accumulation of disability and (ii) identification a trade-off between 
drug efficacy and side effects [31]. DAC was selected for its effects on the depletion of 
Teff cells, concomitant with a reduction in the number of Treg cells and the expansion of 
a particular NK cell subset called CD56bright NK cells [12]. In our model, following the 
administration of DAC, a reduction of Teff cells activation was observed. Furthermore, 
this reduction was visible for Treg cells too, which normally expose the CD25 on their 
surface and use it to sequester IL-2 to Teff cells which result in an indirect inhibition 
mechanism of Teff cells by IL-2 competition [36]. On the other hand, NK cells, trying to 
make up for the lack of T cells, undergo a selective expansion, as expected [12].
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We observed that a dose below 1,000 DAC molecules leads to an insufficient protec-
tion from relapses (i.e. ODC damage), while a dose above 10,000 DAC molecules totally 
depletes the pool of T cells, impairing the mechanisms of protection from external anti-
gens, as shown by the increase of antigen in the system. The right dosage in our model 
should be set to a value between 1,000 and 10,000 DAC molecules, corresponding to 
the actual therapeutic range of 150-300 mg per four weeks consistently with the idea 
that immunosuppressive therapies cannot totally imbalance immune cell homeostasis, 
as a minimal level of immunesurveillance should be always mantained in order to clear 
phatogens. Moreover, simulation results about to the comparison between early and late 
interventions support the current guidelines of therapy for MS, in which is suggested 
that early intervention is crucial for minimize the accumulation of disability [31].
However, some aspects of our modeling framework can be further improved and oth-
ers have to be implemented in order to assert its reliability in representing the disease 
course even in presence of other disease modifying therapies. More specifically, the 
success of therapies tailored against B cells in MS (e.g. ocrelizumab) has shown how B 
cells can contribute to the pathogenesis of MS [37], that for a long time was erroneously 
attributed to T cells only. Also DAC itself has a reduction effect on the B cell population 
in MS [37]. It is worth mentioning that the role of B cells in MS seems to relate on both 
antibody-dependent and antibody-independent functions of these cells [30]. Antibody-
independent functions are represented by the presentation of the antigen to T cells and 
modulation of T cell function by secreting pathogens and / or protective cytokines in 
the CNS [37]. Indeed, the secondary reactivation in the CNS is known to be mediated 
by contact between antigen-presenting cells (e.g. B cells) and self-reactive T cells. These 
important aspects of the relationship between B and T cells in MS pathogenesis are 
worth to be investigated. Moreover, the inclusion of different components and cell types 
in the model will give us the opportunity to model the action of other therapies besides 
DAC.
Conclusions
In this paper we proposed an in silico model based on high level Petri Net formalism 
exploiting Epimod framework. The model has proved to be able to reproduce in silico 
(i) the fine balance between immune activation and regulation during the RRMS dis-
ease course and (ii) the effects of DAC which is a specific therapy tailored against the 
CD25, a molecule expressed on T cells in order to reduce their activation. Even if the 
model is not complete, it takes into account the main actors at the basis of MS immune 
pathogenic process starting from the patients quantification of self-reactive Teff cells 
and Treg cells. Self-reactive Teff cells produce pro-inflammatory cytokines IL-17 and 
IFNγ , which increase during the relapses and are able to damage, first the BBB, and then 
ODCs whereas Treg cells display an impaired function. Of note, our model confirmed 
the importance of a timely intervention on the disease course.
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